MedPath

Influence of Flavonoids on the Absorption of Nintedanib: a Randomized, Cross-Over Pharmacokinetic Study

Conditions
Interstitial Lung disease
Registration Number
NL-OMON23987
Lead Sponsor
Erasmus MC dept. of Medical Oncology and dept. of Pulmonology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
26
Inclusion Criteria

Age =18 years;
- Able to understand the written information and able to give informed consent;
- Planned treatment with nintedanib for any fibrotic ILD according to standard of care.

Exclusion Criteria

- unable to draw blood for study purposes
- usage of other strong P-gP or CYP3A4 interacting compounds
- patients with known impaired drug absorption (e.g. gastrectomy and achlorhydria)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in nintedanib bioavailability, expressed in area under the plasma curve (AUC).
Secondary Outcome Measures
NameTimeMethod
Change in other pharmacokinetic parameters i.e. maximal concentration (Cmax) and time to reach Cmax (Tmax) and a difference in occurrence of (patient reported) toxicity.
© Copyright 2025. All Rights Reserved by MedPath